MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)

MANNKIND CORP

2025-Q1 EPS reported $0.04 revenue$78,354,000

1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).
Royalty revenue $30M (+32%) from increased Tyvaso DPI demand; collaborations & services $29.4M (+18%) from United Therapeutics.
Afrezza NRx grew 20% YoY; sBLA for pediatric approval expected mid-2025.
MNKD-101 Phase 3 ICON-1: 55 patients randomized, 85% sites activated; target 100 patients by YE 2025.
Cash & investments $198M; MNKD-201 (nintedanib DPI) expected to advance to next phase in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.